Apolipoprotein E ε4 allele is associated with Parkinson disease risk in a Mexican Mestizo population

López, Marisol López; Guerrero, Jorge; Yescas, Petra; Boll, Marie‐Catherine; Familiar, Itziar; Ochoa, Adriana; Rasmussen, Astrid; Alonso, María Elisa

doi:10.1002/mds.21340

Cited by 22 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While some studies showed that the presence of APOE -ε4 or APOE -ε2 increases the risk of PD (Huang et al, 2004; Lopez et al, 2007; Pulkes et al, 2011), others showed either a negative or no relationship between apoE genotypes and PD (Gao et al, 2011; Kurz et al, 2009; Williams-Gray et al, 2009). Notably, a large study with 3,465 case and control samples from the NINDS Neurogenetics repository revealed no association between apoE and PD (Federoff et al, 2012).…”

Section: Genetic Clinical and Experimental Evidence For Protective Ementioning

confidence: 99%

HDL and cognition in neurodegenerative disorders

Hottman

Chernick

Cheng

et al. 2014

Neurobiology of Disease

143

129

View full text Add to dashboard Cite

High-density lipoproteins (HDL) are a heterogeneous group of lipoproteins composed of various lipids and proteins. HDL is formed both in the systemic circulation and in the brain. In addition to being a crucial player in the reverse cholesterol transport pathway, HDL possesses a wide range of other functions including anti-oxidation, anti-inflammation, pro-endothelial function, anti-thrombosis, and modulation of immune function. It has been firmly established that high plasma levels of HDL protect against cardiovascular disease. Accumulating evidence indicates that the beneficial role of HDL extends to many other systems including the central nervous system. Cognition is a complex brain function that includes all aspects of perception, thought, and memory. Cognitive function often declines during aging and this decline manifests as cognitive impairment/dementia in age-related and progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A growing concern is that no effective therapy is currently available to prevent or treat these devastating diseases. Emerging evidence suggests that HDL may play a pivotal role in preserving cognitive function under normal and pathological conditions. This review attempts to summarize recent genetic, clinical and experimental evidence for the impact of HDL on cognition in aging and in neurodegenerative disorders as well as the potential of HDL-enhancing approaches to improve cognitive function.

show abstract

Section: Genetic Clinical and Experimental Evidence For Protective Ementioning

confidence: 99%

HDL and cognition in neurodegenerative disorders

Hottman

Chernick

Cheng

et al. 2014

Neurobiology of Disease

143

129

View full text Add to dashboard Cite

show abstract

“…Previous work has suggested ε4 as a risk factor for the age of onset, decline in cognitive impairment, and/or development of dementia in PD, ε2 has also been identified as a potential risk factor in PD, however this is at best a weak effect, and inconsistent across studies (Buchanan et al, 2007; Ezquerra et al, 2008; Gallegos-Arreola et al, 2009; Huang et al, 2006; Huang et al, 2004; Kurz et al, 2009; Lopez et al, 2007; Martinez et al, 2005; Pankratz et al, 2006; Ryu and Kwon, 2010; Vefring et al, 2010). …”

Section: Introductionmentioning

confidence: 99%

A large study reveals no association between APOE and Parkinson's disease

Federoff

Jiménez-Rolando

Nalls

et al. 2012

Neurobiology of Disease

View full text Add to dashboard Cite

Background Research focusing on the role of APOE in Parkinson’s disease (PD) has been largely inconclusive, creating a broad discrepancy in association studies. Objective To elucidate the role of APOE alleles in PD risk by studying a large sample size and controlling for population substructure. Patients and Methods In total, 3465 case and control samples were genotyped, obtained from the NINDS Neurogenetics repository. Results No significant differences in ε4 dosages exist between PD cases and controls. The frequency of ε4 carriers differed slightly between cases and controls at 24% (580/2412) and 26% (270/1053), respectively. Likewise, mean dosages of APOE ε2 were not significantly different between cases and controls. APOE ε2 carriers were observed at a frequency of 13.6% (329/2412) among cases and 15% (158/1053) among controls. Logistic regression models evaluating PD as possibly associated with ε4 or ε2 carrier status and allele dosages yielded no significant results. The mean MMSE score among all PD cases was 28.35 (SD = 2.58) and memory loss was reported in only 11.9% (105/879) of cases. Linear regression models comparing MMSE scores as predicted by ε4 or ε2 carrier status and allele dosages were not significant. Conclusions There is no association between APOE epsilon alleles and Parkinson’s disease.

show abstract

“…In the current work, we report the initial results of a multidisciplinary effort aimed to the analysis of multiple genetic risk factors for PD in a case control sample in Colombia, a South American population; being the first systematic study of several common genetic markers for PD in Latin America. A previous paper reported an association with a single polymorphism in APOE gene in a PD sample from Mexico (López et al 2007). Mean life expectancy for Colombia was 72.3 years in 2005 (Forero et al 2006b).…”

Section: Discussionmentioning

confidence: 97%